Feature | August 11, 2014

Experts Release Updated Guide for the Effective Use of Cardiac Ultrasound Enhancing Agents

August 11, 2014 — Imaging experts from the American Society of Echocardiography (ASE) released a paper, "Guidelines for the Cardiac Sonographer in the Performance of Contrast Echocardiography: A Focused Update from the American Society of Echocardiography,” to help clinicians optimize and demystify the use of ultrasound contrast media in medical imaging. This new guideline aims to expand the use of ultrasound enhancing agents in patient testing, particularly in new and growing areas of cardiovascular care.

The writing group for this updated guideline was chaired by Thomas R. Porter, M.D., FASE, the Theodore F. Hubbard Distinguished Chair of Cardiology at the University of Nebraska Medical Center, in Omaha, Neb. Porter noted that there is “a significant need for sonographers and physicians to be updated on software and techniques that are available to enhance technically difficult echoes, which are most common in overweight patients or those in critical care units who cannot be easily positioned for optimal imaging. This enhancement not only allows sonographers to better detect myocardial ischemia at rest and during stress echocardiography, but also is useful in enhancing Doppler signals and assessing intra-cardiac masses.”

Many technological and clinical advances have occurred since the publication of the original ASE document in 2001, “Guidelines for the Cardiac Sonographer in the Performance of Contrast Echocardiography: Recommendations of the American Society of Echocardiography Council on Cardiac Sonography,” necessitating the need for this update to ensure that clinicians are aware of the new options.  The addition of these intravenous agents has been proven to greatly enhance sub-optimal images and lower the need for repeat imaging studies and thus provide more efficient patient care.

While ultrasound enhancing agents have been commercially available for more than two decades, it is estimated that less than 10 percent of all echocardiograms utilize this valuable tool, despite the fact that at least 20 percent of all echoes are believed to be sub-optimal and would benefit from enhancement. Ultrasound enhancing agents are underutilized today for a wide variety of reasons; both patients and clinicians are often reluctant to use ultrasound contrast because they mistakenly associate it with the contrast agents used for computed tomography (CT) and magnetic resonance imaging (MRI).

While those “classic” contrast agents use ionizing radiation and nephrotoxic agents, ultrasound contrast does not contain either of these, and has a very low incidence of harmful side effects or adverse events. According to Porter, this paper “will help sonographers to better utilize ultrasound enhancing agents and build programs at their institutions by providing important information on the safety and efficacy of ultrasound enhancement in a wide variety of clinical situations.”

In conjunction with the publication of the guideline document, Porter will conduct a live webinar, including a question and answer section, on Sept. 10, 2014 at 1 p.m. ET, which will be available for free to all ASE members and other clinicians for a fee of $25. To facilitate education for those who cannot attend the live webcast, an archived version of this webinar will be available on www.ASEUniversity.org to those who pre-register.

For more information: www.onlinejase.com, www.asecho.org/guidelines

Related Content

Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Hitachi Medical Systems Europe Introduces Third-Generation Intelligent Vector Flow Mapping
News | Cardiovascular Ultrasound | December 07, 2018
Hitachi Medical Systems Europe introduced what it calls the next level of intelligent Vector Flow Mapping (iVFM) at...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
GE Healthcare Unveils New Applications and Smart Devices Built on Edison Platform
Technology | Artificial Intelligence | December 05, 2018
GE Healthcare recently announced new applications and smart devices built on Edison – a platform that helps accelerate...
GE Healthcare Introduces Invenia ABUS 2.0
Technology | Ultrasound Women's Health | December 03, 2018
GE Healthcare recently launched the Invenia automated breast ultrasound (ABUS) 2.0 system in the United States. This...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Videos | Ultrasound Imaging | November 28, 2018
This is an example of the new Fetal HQ heart and vascular software from GE Healthcare for fetal ultrasound.
Artificial Intelligence May Help Reduce Gadolinium Dose in MRI

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

News | Contrast Media | November 27, 2018
Researchers are using artificial intelligence (AI) to reduce the dose of a contrast agent that may be left behind in...
Guerbet Showcases Ongoing Collaboration With IBM Watson at RSNA 2018
News | Clinical Decision Support | November 21, 2018
Guerbet LLC USA will feature its digital solutions including its ongoing collaboration with IBM Watson Health in...
Clarius Mobile Health Announces Clarius AI Collective Intelligence Ultrasound Platform
News | Ultrasound Imaging | November 21, 2018
Clarius Mobile Health will announce a new collective intelligence ultrasound platform at this year's Radiological...